Understanding Gedoogbeleid, Coffeeshop Culture & the Experimentenwet Revolution
| Overall Status | Tolerated (Gedoogbeleid) |
| Coffeeshop Purchase Limit | 5 grams per transaction |
| Personal Possession | Up to 5g tolerated |
| Home Cultivation | Up to 5 plants tolerated |
| Tourist Access | Yes (most cities) |
| Experimentenwet Status | Active in 10 pilot cities |
The Netherlands' unique approach to cannabis regulation centers on the Opiumwet (Opium Act), originally enacted in 1928 and significantly revised in 1976 to create the famous gedoogbeleid (tolerance policy). Under this framework, cannabis remains classified as a Schedule II ("soft drug") substance, technically illegal but tolerated under specific conditions. The 1976 revision established the policy foundation that allows licensed coffeeshops to operate openly while possession of small amounts remains unprosecuted.
The AHOJG criteria govern coffeeshop operations: A (no advertising), H (no hard drugs), O (no nuisance to neighbors), J (no sales to minors under 18), and G (maximum 5 grams per transaction and no more than 500 grams stock). These rules are enforced by local municipalities, which have considerable autonomy in deciding whether to permit coffeeshops and under what additional conditions. Municipal byelaws can impose stricter requirements, including distance requirements from schools (typically 250 meters in Amsterdam) and operating hour restrictions.
The fundamental paradox of Dutch cannabis policy—the achterdeurprobleem (back-door problem)—allows coffeeshops to sell cannabis but provides no legal mechanism for them to obtain it. Supply operations remain illegal, forcing coffeeshops to source from criminal networks. This contradiction has driven the Experimentenwet (Wet experiment gesloten coffeeshopketen), enacted December 13, 2019, which launched operational trials in 2024 testing a fully legal closed supply chain from government-licensed growers to participating coffeeshops in 10 designated municipalities.
The 10 Experimentenwet pilot cities are: Breda, Tilburg, Groningen, Almere, Arnhem, Hellevoetsluis, Maastricht, Nijmegen, Zaanstad, and Heerlen. Ten licensed cultivators supply these municipalities under strict oversight by the CIBG (Central Information Unit for Healthcare Professions). All cannabis products in these cities must come exclusively from licensed sources, with mandatory packaging, testing, and tracking requirements. The experiment runs until at least 2028, with results informing potential nationwide policy changes.
The Netherlands pioneered European medical cannabis with the establishment of the Bureau voor Medicinale Cannabis (BMC) in 2000, becoming the first EU country to provide government-regulated medical cannabis when pharmacy distribution began in September 2003. The BMC operates under the Ministry of Health, Welfare and Sport (VWS), overseeing the entire medical cannabis supply chain from cultivation to patient access.
Bedrocan, the sole licensed medical producer since 2003, cultivates pharmaceutical-grade cannabis at its GMP-certified facility in Veendam. The current product range includes: Bedrocan (22% THC, sativa), Bedrobinol (13.5% THC, indica), Bediol (6.3% THC, 8% CBD), Bedica (14% THC, indica granulate), and Bedrolite (<1% THC, 9% CBD). These products are available as dried flower, cannabis oil, and granulate forms. All products undergo rigorous testing for potency, pesticides, heavy metals, and microbial contamination.
Approximately 20,000 patients currently access medical cannabis through Dutch pharmacies in 2026. Patients require a prescription from any licensed physician; no specialist referral is needed. However, insurance coverage remains inconsistent—most basic health insurance (basispakket) does not cover medical cannabis, meaning patients typically pay €8-12 per gram out of pocket. Some supplementary policies (aanvullende verzekering) partially reimburse cannabis medication. The BMC reports annual medical cannabis dispensing of approximately 3,000 kilograms domestically, with additional significant exports to Germany, Italy, and other European medical programs.
The Dutch coffeeshop sector generates an estimated €500-700 million in annual turnover as of 2026, though exact figures are difficult to verify given the semi-legal nature of supply operations. The 570 licensed coffeeshops represent a significant decline from the peak of over 1,500 establishments in the 1990s, driven by municipal consolidation policies, stricter enforcement, and the elimination of many smaller operators. Amsterdam alone hosts approximately 160 coffeeshops, representing nearly 30% of the national total.
The Experimentenwet introduced the first fully legal cultivation framework, with 10 approved growers now supplying the 10 pilot municipalities. These licensed cultivators operate under strict protocols including seed-to-sale tracking, mandatory lab testing, standardized packaging with THC/CBD content labels, and regular compliance inspections. Early data from Breda and Tilburg show promising results, with coffeeshop operators reporting consistent quality and supply stability previously impossible under the illegal sourcing model.
The Dutch CBD market has grown substantially to approximately €50 million annually, operating under EU Novel Food regulations for ingestibles and cosmetic regulations for topicals. CBD products containing under 0.2% THC are fully legal and widely available at health stores, pharmacies, and specialized retailers. Major Dutch and international brands including Jacob Hooy, Lucovitaal, and Cibdol dominate the market. The BMC medical program serves approximately 20,000 patients and exports Bedrocan products to 10+ countries, generating significant pharmaceutical export revenue.
The Netherlands' cannabis culture traces its roots to the counterculture movements of the 1960s, when Amsterdam's liberal atmosphere attracted youth from across Europe. The first proto-coffeeshops emerged in Amsterdam's Jordaan and De Pijp neighborhoods by 1972, operating as semi-clandestine "house dealers" in bars and youth centers. The pione
Health & Science writer with nursing background, specializing in medical cannabis research.
Yes, in most Dutch cities including Amsterdam, tourists 18+ can buy cannabis at licensed coffeeshops with valid photo ID. The limit is 5g per transaction. Some municipalities including Maastricht have restricted access to residents only. The Experimentenwet cities operate under different rules during the supply-chain pilot phase.
Technically no. Cannabis remains a controlled substance under the Dutch Opium Act (Opiumwet). What exists is a formal gedoogbeleid (tolerance policy): coffeeshop retail, personal possession up to 5g, and home cultivation of up to 5 plants are tolerated rather than prosecuted. The supply side remains illegal, creating the achterdeurprobleem (back-door problem) that the Experimentenwet aims to solve.
The Experiment Gesloten Coffeeshopketen tests a fully legal supply chain from licensed growers to coffeeshops in 10 Dutch cities. Launched in 2024, participating cities include Breda, Tilburg, Groningen, and Almere. Licensed growers supply cannabis under full government oversight. Results will inform Netherlands cannabis policy decisions after 2026.
Approximately 570 licensed coffeeshops operate in the Netherlands as of 2026, down from over 1,500 in the 1990s. Amsterdam has approximately 160 coffeeshops. Many municipalities have imposed moratoriums on new licenses and actively reduced numbers over the past two decades.
Public consumption of cannabis is technically illegal under the Opium Act despite the gedoogbeleid. In practice, enforcement varies by municipality. Amsterdam tolerates outdoor consumption in many areas but not near schools, in parks, or on public transport. Police may issue warnings or fines. The Experimentenwet cities may have stricter rules in public spaces during the pilot.